Aethlon Medical Inc (AEMD)

[ANESRI]

Transformational Medical Technologies Initiative
(TMTI)
The objective of the TMTI is to develop broad-spectrum therapeutic
countermeasures to mitigate the effects of exposure to the Warfighter from
emerging or genetically-engineered biological threats. The TMTI strategy is to
accelerate the development of new medicines by establishing alliances with
academia and the pharmaceutical and bio-technology industries. Through this
alliance, applicable drug candidates will be identified and incorporated into the
program. Proactive technology scanning and directed development through
targeted solicitations will be initiated to broaden the scope of therapies for
consideration.
JOINT PROJECT Transformational Medical Technologies Initiative | Medical | Biological Therapeutics
CONTRACTOR(S)/GOVERNMENT PERFORMERS
U.S. Army U.S. Navy U.S. Air Force U.S. Marine Corps U.S. Coast Guard National Guard U.S. Army Reserve U.S. SOCOM
Homeland Defense DoD Other Agencies Academia Foreign Military
NSN: Unavailable
USER(S)
IN DEVELOPMENT
SCHEDULE FY09 FY10 FY11
Contract #1-6 (HFV) Phase I trials
Contract #1-4 (IBF) Phase I trials
MS B Decision (Hemorrhagic Fever Viruses)
Contract #1-2 Phase II Pivotal Animal Studies